Home > Boards > US OTC > Biotechs > Cytodyn Inc. (CYDY)

Pharma has folks internally that focus on publication

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Beachbum3232 Member Profile
 
Followed By 3
Posts 75
Boards Moderated 0
Alias Born 02/20/19
160x600 placeholder
Current Report Filing (8-k) Edgar (US Regulatory) - 6/15/2021 5:01:59 PM
Amended Statement of Beneficial Ownership (sc 13d/a) Edgar (US Regulatory) - 6/8/2021 4:32:22 PM
CEO's Presenting at Emerging Growth Conference Virtually Tomorrow InvestorsHub NewsWire - 6/8/2021 7:00:00 AM
CytoDyn's partner to submit request to conduct Phase 3 leronlimab studies in Brazil Seeking Alpha - 5/27/2021 6:33:58 AM
Statement of Beneficial Ownership (sc 13d) Edgar (US Regulatory) - 5/24/2021 5:16:01 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/20/2021 5:18:50 PM
CytoDyn promotes Antonio Migliarese to CFO role Seeking Alpha - 5/20/2021 5:14:56 PM
IQST Signals BUY InvestorsHub NewsWire - 5/20/2021 9:43:19 AM
CytoDyn to submit CD12 trial data to regulatory agencies in multiple countries Seeking Alpha - 5/18/2021 7:45:54 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/17/2021 5:02:38 PM
CytoDyn plunges as FDA rebukes its clinical trials for COVID-19 therapy Seeking Alpha - 5/17/2021 3:51:07 PM
CytoDyn inks leronlimab distribution deal in India for COVID-19 Seeking Alpha - 5/13/2021 9:04:20 AM
CEO Presenting at Emerging Growth Conference Virtually This Week InvestorsHub NewsWire - 5/10/2021 7:00:00 AM
CytoDyn to conduct two COVID-19 trials in Brazil Seeking Alpha - 5/5/2021 6:25:40 AM
CytoDyn provides updates on leronlimab HIV extension arm; to hold webcast on May 5 on multiple initiatives Seeking Alpha - 5/3/2021 9:46:59 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/29/2021 4:32:06 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 4/21/2021 6:28:13 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/21/2021 4:31:54 PM
CytoDyn initiates rolling submission of leronlimab in COVID-19 to Canada regulator Seeking Alpha - 4/19/2021 6:54:58 AM
CytoDyn executes supply and distribution agreement with Chiral Pharma Seeking Alpha - 4/15/2021 9:34:25 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/12/2021 4:31:04 PM
CytoDyn completes enrollment in COVID-19 long-hauler trial Seeking Alpha - 4/9/2021 6:59:31 AM
CytoDyn updates on leronlimab-treated COVID-19 patient Seeking Alpha - 4/5/2021 11:51:19 AM
CytoDyn to provide full update on its activities on April 6 Seeking Alpha - 4/1/2021 6:19:48 AM
CytoDyn files new protocol with FDA for 4 doses of leronlimab for critical COVID-19 Seeking Alpha - 4/1/2021 6:13:14 AM
Beachbum3232   Tuesday, 08/04/20 11:51:09 AM
Re: misiu143 post# 101961
Post # of 170706 
Pharma has folks internally that focus on publication planning as part of their responsibility. In essence, get the data published so that we can then cite it but also, buy reprints for our field sales folks, and med affiars teams when requests come in. On the vendor side there are folks who do this all day on behalf of pharma clients. Usually, these pub planning/med communication folks, have ties at these major publishing houses and have influence on what gets published and when. Go to this site and look up leronlimab

https://pubmed.ncbi.nlm.nih.gov/

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences